AutoInfusors feature a primary drug container, fluid delivery path and drive mechanism designed to address the specific requirement of the drug and its target patient.

The device is attached onto the injection site and when the activation button is pushed, the drug automatically infuses into the subcutaneous tissue.

A series of audible, tactile and visual indicators can signal to the patient when the full dose has been delivered to remove the device from the body.

Unilife CEO Alan Shortall said for clinical trial purposes, the AutoInfusor can either be filled at the time of use for the convenience of pharmaceutical customers, or supplied in a prefilled format.

"With Unilife, pharmaceutical and biotechnology companies now have the option of selecting a single partner in the development and commercial supply of differentiated devices that can help to enable, enhance and extend the commercial lifecycles of their injectable drugs and vaccines," Shortall said.